News Releases

Filter News Releases by year:
2024 | 2023 | 2022 | 2021 | 2020

46 Results

November 2021

Too Many People with HIV Fail to Achieve Durable Viral Suppression

November 29, 2021

Among people with HIV worldwide who are receiving antiretroviral therapy (ART), adults are getting closer to the global target of 95% achieving viral suppression, but progress among children and adolescents is lagging and long-term viral suppression among all groups remains a challenge. These findings of a study funded by the National Institutes of Health suggest that substantial efforts are needed to help people with HIV durably suppress the virus. The findings were published today in the journal The Lancet HIV.

October 2021

NIH Researchers Identify How Two People Controlled HIV After Stopping Treatment

October 28, 2021

Research led by scientists at the National Institutes of Health has identified two distinct ways that people with HIV can control the virus for an extended period after stopping antiretroviral therapy (ART) under medical supervision. This information could inform efforts to develop new tools to help people with HIV put the virus into remission without taking lifelong medication, which can have long-term side-effects. 

August 2021

HIV Vaccine Candidate Does Not Sufficiently Protect Women Against HIV Infection

August 31, 2021

An investigational HIV vaccine tested in the “Imbokodo” clinical trial conducted in sub-Saharan Africa posed no safety concerns but did not provide sufficient protection against HIV infection, according to a primary analysis of the study data. The Phase 2b proof-of-concept study, which began in November 2017, enrolled 2,637 women ages 18 to 35 years from five countries.

NIH Makes Substantial New Investment in HIV Cure Research

August 17, 2021

The National Institutes of Health has awarded approximately $53 million in annual funding over the next five years to 10 research organizations in a continued effort to find a cure for HIV. The new awards for the Martin Delaney Collaboratories for HIV Cure Research program further expand the initiative’s 2016 renewal from six institutions to 10, and represent a funding increase of approximately 75 percent.

July 2021

NIH Awards More than $20 Million to International HIV Database Centers

July 22, 2021

The National Institutes of Health has renewed grants to seven regional centers that compose the International epidemiology Databases to Evaluate AIDS (IeDEA), awarding $20.8 million in first-year funding. The 15-year-old IeDEA program efficiently advances knowledge about HIV by pooling and analyzing de-identified health data from more than two million people with HIV on five continents to answer research questions that individual studies cannot address. The grants are expected to last five years and to total an estimated $100 million.  

April 2021

NIH Experts Call for Accelerated Research to Address Concurrent HIV and COVID-19 Pandemics

April 8, 2021

The COVID-19 pandemic is affecting people with or at risk for HIV both indirectly, by interfering with HIV treatment and prevention services, and directly, by threatening individual health. An effective response to these dual pandemics requires unprecedented collaboration to accelerate basic and clinical research, as well as implementation science to expeditiously introduce evidence-based strategies into real-world settings. This message comes from a review article co-authored by Anthony S.

February 2021

To End HIV Epidemic, We Must Address Health Disparities

February 19, 2021

NIH reports that scientific strides in HIV treatment and prevention have reduced transmissions and HIV-related deaths significantly in the US.

January 2021

Antibody Infusions Prevent Acquisition of Some HIV Strains, NIH Studies Find

January 26, 2021

NIH finds that an investigational anti-HIV antibody prevented acquisition of some HIV strains, but did not significantly reduce overall acquisition.

December 2020

NIH Statement on World AIDS Day 2020

December 1, 2020

Today on World AIDS Day, we reflect both on the remarkable progress that has been made against HIV as well as the considerable challenges that remain. We now have highly effective HIV treatment and prevention methods, and work is underway to address the remaining challenges in delivering these tools to the people who need them most, as well as to develop new interventions. The National Institutes of Health continues to advance rigorous, innovative research to prevent new HIV transmissions and improve the health of people with HIV worldwide. 

November 2020

NIH Announces Restructured HIV Clinical Trials Networks

November 30, 2020

NIAID announced the clinical investigators and institutions that will lead four NIH HIV clinical trials networks over the next seven years.

Statement—NIH Study Finds Long-Acting Injectable Drug Prevents HIV Acquisition in Cisgender Women

November 9, 2020

A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every eight weeks was safe and more effective than a daily oral PrEP regimen at preventing HIV acquisition among a group of cisgender women. The women, from southern and east Africa, are enrolled in a clinical trial sponsored by the National Institutes of Health.

July 2020

Vaginal Ring for HIV Prevention Receives Positive Opinion from European Regulator

July 24, 2020

The European Medicines Agency (EMA) announces its adoption of a positive opinion on vaginal ring for HIV prevention.

Kidney Transplantation Between People with HIV is Safe, NIH Study Finds

July 23, 2020

NIH Study finds that kidney transplantation between people with HIV is safe, making more kidneys available for those awaiting a transplant.

Long-Acting Injectable Form of HIV Prevention Outperforms Daily Pill in NIH Study

July 7, 2020

In a recent NIH study, a long-acting injectable form of HIV prevention outperformed a daily pill.

May 2020

Long-Acting Injectable Drug Prevents HIV Among Men Who Have Sex with Men and Transgender Women

May 18, 2020

NIH study shows investigational long-acting form of the HIV drug cabotegravir prevents HIV acquisition in men and transgender women who have sex with men.

March 2020

Newer Anti-HIV Drugs Safest, Most Effective During Pregnancy

March 11, 2020

The antiretroviral drugs dolutegravir and emtricitabine/tenofovir alafenamide fumarate (DTG+FTC/TAF) may comprise the safest and most effective HIV treatment regimen currently available during pregnancy, researchers announced today. Their findings come from a multinational study of more than 640 pregnant women with HIV across four continents. The study results affirm updated recommendations for HIV treatment in pregnant women set forth by the World Health Organization (WHO).

Drug-Delivery Technology Leads to Sustained HIV Antibody Production in NIH Study

March 9, 2020

An NIH study finds that a new drug-delivery technology leads to sustained HIV antibody production.

NIH Study Finds Lower Concentration of PrEP Drug in Pregnant Young Women

March 9, 2020

Among African adolescent girls and young women who took HIV pre-exposure prophylaxis (PrEP) daily, levels of the PrEP drug tenofovir were more than 30% lower in those who were pregnant than in those who had recently given birth. All 40 study participants took PrEP under direct observation, confirming their near-perfect adherence. PrEP drug levels were lower to a similar degree in the pregnant African adolescent girls and young women compared to American men and non-pregnant, non-lactating women who took PrEP daily under direct observation in an earlier study.

February 2020

NIH-Funded Clinical Trial to Test PrEP, Dapivirine Ring for Safety in Pregnant Women

February 10, 2020

The first clinical trial specifically designed to test the safety of the monthly dapivirine vaginal ring in pregnant women has begun in southern and eastern Africa. The National Institutes of Health-funded study also will test the safety of a daily oral antiviral tablet for HIV pre-exposure prophylaxis (PrEP) in pregnant women and will assess how much they accept and use these two HIV prevention tools. The study will complement an ongoing NIH-funded trial of PrEP in adolescents and young women during pregnancy and the first six months after birth.

Experimental HIV Vaccine Regimen Ineffective in Preventing HIV

February 3, 2020

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has stopped administration of vaccinations in its HVTN 702 clinical trial of an investigational HIV vaccine. This action was taken because an independent data and safety monitoring board (DSMB) found during an interim review that the regimen did not prevent HIV. Importantly, the DSMB did not express any concern regarding participant safety. 

January 2020

NIH-Supported Scientists Reverse HIV and SIV Latency in Two Animal Models

January 22, 2020

In a range of experiments, scientists have reactivated resting immune cells that were latently infected with HIV or its monkey relative, SIV, in cells in the bloodstream and a variety of tissues in animals. As a result, the cells started making copies of the viruses, which could potentially be neutralized by anti-HIV drugs and the immune system. This advance, published today in two papers in the journal Nature, marks progress toward a widely accessible cure for HIV.